WASHINGTON (AP) — The Food and Drug Administration commissioner's effort to drastically shorten the review of drugs favored by President Donald Trump's administration is causing alarm across the ...
The proposed changes are relatively modest, yet they represent an important procedural step forward in the implementation of ...
The proposal, issued by the Centers for Medicare & Medicaid Services (CMS), targets hospitals participating in the federal ...
As the Trump administration begins to make its mark on the Medicare drug price negotiation program, litigation over the program continues. In the two years since the first case challenging the program ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results